Immunology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

RSV Vaccine in Transplant Recipients

This Phase 3 trial led by the University Health Network in Toronto is testing a new vaccine designed to protect adult lung and stem cell transplant recipients from respiratory syncytial virus (RSV) infections. People with weakened immune systems often do not respond well to vaccines, making RSV a serious threat. This study is important because it could offer better protection for transplant patients, helping to reduce severe RSV illness through a specially formulated vaccine.

Genomics and COVID-19 Vaccine Adverse Events

Researchers at the University of British Columbia are exploring why some people have immune-related side effects after receiving COVID-19 vaccines. By studying the genetic factors behind these reactions, this research aims to identify individuals who might be at higher risk and improve vaccine safety for everyone. With over 6,000 participants involved, this study could help make vaccines safer and more personalized in the future.

Direct Oral Challenges in Private Practice Setting to Delabeling Children With Beta-lactam Allergy

This trial in France is examining a method to better diagnose mild allergic reactions to beta-lactam antibiotics in children. Using a direct oral challenge, doctors can confirm whether a child is truly allergic or not. This approach could prevent unnecessary restrictions on antibiotic use, allowing more children to receive effective treatments without fear of allergic reactions.

Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS)

The University Hospital in Lille completed a study focused on a specific type of immune cell, called 4BL B cells, in people with multiple sclerosis. Understanding how these cells work may reveal new ways to treat MS by reducing inflammation and improving symptoms. Although the study has finished, its findings could guide future therapies to better manage this chronic condition.

Safety, Efficacy of FFP From Healthy Donors to Ameliorate Frailty and Enhance Immune Function in Older Individuals

This Phase 1 trial in the United States is testing whether monthly transfusions of plasma from young healthy donors can improve frailty and immune function in older adults. If successful, this treatment could offer a new way to enhance quality of life and cognitive health for elderly individuals facing frailty. Participants are followed for a year to monitor safety and lasting benefits.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.